Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419874 | 0.94 | ALDH1A1 (0.32) | — | |
| SCHEMBL5657143 | 0.88 | — | — | |
| SCHEMBL5414602 | 0.87 | KDM4E (0.31) | — | |
| SCHEMBL5411979 | 0.86 | MAOB (0.32) | SLC6A4BCHEMAOAACHEMAOB | |
| SCHEMBL4035884 | 0.82 | CACNA1H (0.36) | SLC6A4BCHEMAOAACHEMAOB | |
| SCHEMBL5414669 | 0.81 | HTR1B (0.38) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL4038349 | 0.81 | CACNA1H (0.35) | SLC6A4BCHEMAOAACHEMAOB | |
| SCHEMBL4035177 | 0.81 | HRH3 (0.36) | BCHEMAOAACHEMAOB | |
| SCHEMBL5421711 | 0.80 | KDM4E (0.34) | BCHEMAOAACHEMAOB | |
| SCHEMBL5430878 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262309-B2 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) | 2007-08-28 | — | — | US | claimed |
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2007-07-26 | — | — | US | claimed |
| EP-1492795-B1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2005-11-16 | — | — | EP | claimed |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.D.D. (HR) | 2005-06-23 | — | — | US | claimed |
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | claimed |
| US-7262309-B2 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | GLAXOSMITH KLINE ISTRAZIVOCKI CENTAR ZAGREB, D.O.O. (HR) | 2007-08-28 | — | — | US | disclosed |
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2007-07-26 | — | — | US | disclosed |
| EP-1708696-A1 | USE OF BENZONAPHTHOAZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2006-10-11 | — | — | EP | disclosed |
| EP-1492795-B1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA ISTRAZIVACKI INST D O O (HR) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005072728-A1 | USE OF BENZONAPHTHOAZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2005-08-11 | — | — | WO | disclosed |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.D.D. (HR) | 2005-06-23 | — | — | US | disclosed |
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-06-16 | — | — | US | disclosed |
| EP-1492795-A1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084961-A1 | 1- OR 3-THIA-BENZONAPHTHOAZULENES AS INHIBITORS OF TUMOUR NECROSIS FACTOR PRODUCTION AND INTERMEDIATES FOR THE PREPARATION THEREOF | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130964-A1 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | SLC6A4 3906/4885BCHE 1240/4885MAOA 1255/4885 |
| US-20050137249-A1 | 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | TNF, IL1A, IL1B | SLC6A4 4202/4885BCHE 670/4885MAOA 1102/4885 |
| US-20070173499-A1 | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | BCHE, GAP43, DBH | SLC6A4 93/4885BCHE 1/4885MAOA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.